Anti-chlamydophila antibiotic combination therapy in the treatment of patients with Coronary Heart Disease

This study is testing whether a combination of three antibiotics — doxycycline, azithromycin, and rifabutin — can safely treat coronary artery disease (blocked heart arteries) that has not responded well to standard treatment. The researchers think that a bacteria called Chlamydophila pneumoniae, which can live inside the artery walls, may be causing inflammation that leads to blockages. Participants will take the antibiotic combination or a placebo for 90 days and be monitored for safety, quality of life, and changes in their heart arteries. You may be eligible if: - You are aged 18 to 80 years - You are male, or a female who cannot become pregnant (due to hysterectomy, tubal ligation, or being at least one year post-menopause) - You have documented recent acute coronary syndrome or evidence of heart muscle ischaemia (reduced blood flow to the heart) - You have been identified as suitable for a staged coronary procedure (PCI) You may NOT be eligible if: - You are a woman who could become pregnant - You have significant blood, liver, kidney, neurological, or psychiatric disease - You are allergic to any of the antibiotics used - You drink heavily (more than 60g alcohol/day for men, 40g/day for women) - You have been in another drug trial in the past 4 weeks Talk to your doctor about whether this trial might be right for you.